Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02983006 · ClinicalTrials.gov registry record · Phase 1
Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02983006 is a Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 12 participants.
The verdict
NCT02983006, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety profile, tolerability, and immunoregulatory (pharmacodynamic; PD) activity of DS-8273a administered in combination with nivolumab (anti-PD-1 antibody) to subjects with unresectable Stage III or Stage IV melanoma.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL DS-8273a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-10 |
| Est. Completion | 2021-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02983006
The ClinicalTrials.gov registry entry for NCT02983006 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02983006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02983006 about?
NCT02983006 is a clinical study titled "Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma". The purpose of this study is to evaluate the safety profile, tolerability, and immunoregulatory (pharmacodynamic; PD) activity of DS-8273a administered in combination with nivolumab (anti-PD-1 antibody) to subjects with unresectable Stage III or Stage IV melanoma.
What is the current status of trial NCT02983006?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2016-10. Estimated completion is 2021-01-01.
What interventions are being tested in trial NCT02983006?
The interventions under investigation include: Nivolumab (BIOLOGICAL), DS-8273a (BIOLOGICAL).
Who is sponsoring clinical trial NCT02983006?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.